2017 American Transplant Congress
In Clinic Systems to Address Adherence Barriers Decrease Late Allograft Rejection for Kidney Transplant Patients.
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background: Patient-identified barriers to taking immunosuppressive medications are associated with rejection and allograft loss in kidney transplant patients, yet interventions targeting adherence barriers are rarely…2017 American Transplant Congress
Co-Stimulation Blockade to Minimize and Withdraw Long Term Calcineurin Inhibitors (CNI) in Simultaneous Pancreas and Kidney Transplant (SPK).
The NIH multicenter CTOT-15 trial tested the hypothesis that use of belatacept (bela) could minimize or eliminate long-term CNI use in simultaneous pancreas and kidney…2017 American Transplant Congress
A Promising MyD88 Inhibitor TJ-M2010-2 Protects Heart from Myocardial Ischemia Reperfusion Injury.
BACKGROUND: The activation of innate immunity via myeloid differentiation factor 88 (MyD88) contributes to myocardial ischemia reperfusion injury (IRI). This study is to investigate the…2017 American Transplant Congress
A Lower Mean Exposure to Tacrolimus, Not Intra-Patient Variability Is Associated with Chronic Active Antibody Mediated Rejection.
Introduction. Chronic active antibody mediated rejection (caABMR) is one of the major causes of long-term kidney graft loss. It is hypothesized that frequent underexposure and…2017 American Transplant Congress
Diabetes in Liver Transplantation: Evaluation of Management and Associated Clinical Outcomes.
PurposeThere is limited data with diabetes management in liver transplant recipients and associated outcomes, this study aims to evaluate the long-term diabetes management in this…2017 American Transplant Congress
Improvement of Cyclosporine A Dosing Strategy to Enhance Medication Adherence.
Background: It is known that the number of daily pills is crucial for medical adherence of patients after heart transplantation (HTx). For cyclosporine A (CsA)…2017 American Transplant Congress
Immunosuppressive Role of Pancreas Derived Mesenchymal Stem Cells.
BackgroundThe Edmonton protocol revived islet transplantation therapy for Type-1 Diabetic patients. However, Long-term islet function still remains a challenge. Immunosuppression used after islet transplantation contributes…2017 American Transplant Congress
Comparison of Long Term Renal Function Outcomes for Everolimus (EVR) vs. Sirolimus (SIR) vs. Mycophenolate Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant (Ktx).
MPA or mammalian target of rapamycin inhibitors (mTORi [EVR or SIR]) in combination with calcineurin inhibitors (CNI, tacrolimus [TAC] or cyclosporine) are used for maintenance…2017 American Transplant Congress
Early Exposure of Everolimus with and without Calcineurin Inhibitors.
Nephrology Division, Hospital do Rim, UNIFESP, São Paulo, SP, Brazil
This study aimed to evaluate the effect of cyclosporine (CSA) or tacrolimus (TAC) on early exposure of everolimus (EVR).A cohort of 306 kidney transplant recipients…2017 American Transplant Congress
Subclinical Histologic Findings Are Observed in 25% of Stable Adult Liver Transplant Recipients (ALTRs) Screened for Immunosuppression Withdrawal (ISW): OPTIMAL (NCT02533180).
OPTIMAL is a 6-center ISW study in non-autoimmune, non-HCV ALTRs ≥3 yrs post-transplant (tx). Studies have shown a correlation between portal inflammation associated with tissue…
- « Previous Page
- 1
- …
- 91
- 92
- 93
- 94
- 95
- …
- 138
- Next Page »